A detailed history of Jump Financial, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Jump Financial, LLC holds 19,970 shares of BMRN stock, worth $1.27 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
19,970
Holding current value
$1.27 Million
% of portfolio
0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$69.02 - $93.84 $1.38 Million - $1.87 Million
19,970 New
19,970 $1.4 Million
Q1 2024

May 13, 2024

BUY
$83.81 - $99.0 $59,253 - $69,993
707 Added 28.36%
3,200 $279,000
Q4 2023

Oct 21, 2024

SELL
$76.22 - $98.51 $485,216 - $627,114
-6,366 Reduced 71.86%
2,493 $240,000
Q4 2023

Feb 07, 2024

SELL
$76.22 - $98.51 $485,216 - $627,114
-6,366 Reduced 71.86%
2,493 $240,000
Q3 2023

Oct 21, 2024

SELL
$85.07 - $94.48 $5.17 Million - $5.74 Million
-60,719 Reduced 87.27%
8,859 $783,000
Q3 2023

Nov 07, 2023

SELL
$85.07 - $94.48 $5.17 Million - $5.74 Million
-60,719 Reduced 87.27%
8,859 $783,000
Q2 2023

Oct 21, 2024

BUY
$86.68 - $100.3 $6.03 Million - $6.98 Million
69,578 New
69,578 $6.03 Million
Q2 2023

Aug 07, 2023

BUY
$86.68 - $100.3 $6.03 Million - $6.98 Million
69,578 New
69,578 $6.03 Million
Q3 2022

Nov 07, 2022

SELL
$82.16 - $96.94 $276,468 - $326,203
-3,365 Reduced 41.67%
4,711 $400,000
Q2 2022

Aug 09, 2022

SELL
$71.48 - $86.85 $3.24 Million - $3.94 Million
-45,385 Reduced 84.89%
8,076 $670,000
Q1 2022

May 12, 2022

BUY
$74.28 - $92.69 $3.63 Million - $4.52 Million
48,813 Added 1050.19%
53,461 $4.12 Million
Q4 2021

Feb 10, 2022

SELL
$71.72 - $91.47 $1.18 Million - $1.5 Million
-16,452 Reduced 77.97%
4,648 $411,000
Q3 2021

Nov 12, 2021

BUY
$74.77 - $85.47 $1.58 Million - $1.8 Million
21,100 New
21,100 $1.63 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Jump Financial, LLC Portfolio

Follow Jump Financial, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jump Financial, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jump Financial, LLC with notifications on news.